## 510(k) Summary 807.92(c)

FEB - 9 2010

**SPONSOR** 

807.92(a)(1)

Company Name: Company Address

JMS North America Corporation 22320 Foothill Blvd., Suite 350

Hayward, CA 94541

**USA** 

Telephone:

(510) 888-9090

Fax:

(510) 888-9099

Contact Person:

Shinya Nagase

Summary Preparation Date: November 23, 2009

**DEVICE NAME** 

807.92(a)(2)

Trade Name:

JMS Blunt A.V. Fistula Needle Set with Site Preparation

Tool

Common/Usual Name:

Fistula Needle

Classification Name:

Fistula Needle

Regulation Number:

876.5540

Product Code:

FIE

Device Class:

Class II

Panel:

Gastroenterology/Urology

#### PREDICATE DEVICE

807.92(a)(3)

Legally Marketed Equivalent Device

Company

Product

510(k) #

JMS North America Corp.

A.V. Fistula Blunt Needle Set

K082882

#### DEVICE DESCRIPTION

807.92(a)(4)

JMS A.V. Fistula Blunt Needle Set with Site Preparation Tool is a modification of the previously cleared JMS A.V. Fistula Blunt Needle Set (K082882). The modification is the replacement of the standard needle cover with a site preparation tool "scraper" feature that removes the scabs that have developed over the constant site prior to cannulation.

#### **DEVICE INTENDED USE**

807.92(a)(5)

The JMS Blunt A.V. Fistula Needle Set with Site Preparation Tool is intended for temporary cannulation (non-implantable, less than 30 days) to vascular access for extracorporeal blood treatment and for the removal of scabs that have developed over the constant site prior to cannulation. The device is intended for single use only. The JMS AV Fistula Blunt Needle Set is for use on developed 'constant site' access sites.

COMPARISON OF TECHNICAL CHARACTERISTICS 8	807.92(a)(6)
---	--------------

The second of th	A CONTRACT OF THE STATE OF STATE OF STATE OF THE STATE OF			
New Device	Predicate Device			
A.V. Fistula Blunt Needle Set with	A.V. Fistula Blunt Needle Set			
JMS Singapore Pte Ltd	JMS Singapore Pte Ltd			
	K082882			
Device is used for needle insertion into	Device is used for needle insertion into			
a previously mature access site for	a previously mature access site for			
dialysis procedure using a constant-site	dialysis procedure using a constant-site			
technique of needle insertion. The	technique of needle insertion.			
modification of the predicate device	_			
consists of a Site Preparation Tool				
incorporated into the needle cover that				
use of a "scraper" feature to remove the				
scabs that have developed over the				
<u>-</u>				
1				
Similarities 25				
Same	Same			
Same	Same			
Met established acceptance criteria	Met established acceptance criteria			
Same	Same			
Same	Same			
All patient contacting materials meet	All patient contacting materials meet			
biocompatibility standards for ISO-	biocompatibility standards for ISO-			
10993 for non-implanted blood access	10993 for non-implanted blood access			
contacting device less than 30 days	contacting device less than 30 days			
Differences				
A THE PARTY OF THE	the ball to the transfer of the ball to be a second of the ball to be a sec			
Needle Cover with Site Preparation	Needle Cover			
	A.V. Fistula Blunt Needle Set with  Site Preparation Tool  JMS Singapore Pte Ltd  Device is used for needle insertion into a previously mature access site for dialysis procedure using a constant-site technique of needle insertion. The modification of the predicate device consists of a Site Preparation Tool incorporated into the needle cover that allows for site preparation through the use of a "scraper" feature to remove the scabs that have developed over the constant site prior to cannulation.  Similarities  Same  Same  Met established acceptance criteria  Same  All patient contacting materials meet biocompatibility standards for ISO-10993 for non-implanted blood access contacting device less than 30 days			

### **SAFETY and EFFECTIVENESS**

807.92(b)

Testing information demonstrating safety and effectiveness of JMS A.V. Fistula Blunt Needle Set in the intended environment of use is supported by testing that was conducted in accordance with the following standards:

	Standard	Title
1	ISO 11135:1994	Medical Devices – Validation and
		Routine control of ethylene oxide sterilization
2	ISO 14971:2000	Medical Device – Application of risk management to medical devices

K 093637 Puzz 3.f3

#### BIOCOMPATIBILITY

We have assessed all of our patient contacting materials for biocompatibility requirements in accordance with the May 1, 1995 FDA Biocompatibility Guidance, the FDA-modified matrix of the "International Standard ISO-10993", Biological Evaluation of Medical Devices Part 1: Evaluation and Testing", including the flow chart entitled "Biocompatibility Flow Chart for the Selection of Toxicity Tests for 510(k)s.

#### **STERILIZATION**

The device is sterilized using ETO, utilizing the ISO International Standard 11135 (EN 550). The validations were performed in accordance with EN-550 and ISO 11135.

#### PERFORMANCE DATA

A clinical usability study was performed to verify ease of use and label comprehension.

CONCLUSION 807.92(b)(3)

The JMS Blunt A.V. Fistula Needle Set with Site Preparation Tool is a modification of the predicate, JMS Blunt AV Fistula Needle Set (K K082882) and is the same device in its technological and performance characteristics. The addition of a site preparation tool incorporated into the needle cover has changed the Indications for Use to include this feature. Risk Analysis, Design Control and a Clinical Usability Study has verified its safe and effective use.

#### **DEPARTMENT OF HEALTH & HUMAN SERVICES**



Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G60 Silver Spring, MD 20993-0002

JMS North America Corporation c/o E. J. Smith, President Smith Associates 1468 Harwell Avenue CROFTON MD 21114

FFR - 9 2010

Re: K093637

Trade/Device Name: JMS Blunt AV Fistula Needle Set with Site Preparation Tool

Regulation Name: Blood access device and accessories

Regulation Number: 21 CFR §876.5540

Regulatory Class: II Product Code: FIE

Dated: November 23, 2009 Received: November 24, 2009

Dear Mr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related

adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours

Janine M. Morris

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# **Indications for Use**

510(k) Number (if known): <u>K093637</u>

Device Name: JMS Blunt AV Fistula Needle Set with Site Preparation Tool

Indications for Use:

The JMS Blunt AV Fistula Needle Set with Site Preparation Tool is intended for temporary cannulation (non-implantable, less than 30 days) to vascular access for extracorporeal blood treatment and for the removal of scabs that have developed over the constant site prior to cannulation. The device is intended for single use only. The JMS AV Fistula Blunt Needle Set is for use on developed 'constant site' access sites.

# (Check appropriate designation below)

Prescription Use√ (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELO	W THIS LIN OF NEEDEI	E-CONTINUE ON ANOTHER PAGE D)
Concurrence of CDR (Division Sign-Off) Division of Reprote Radiological Device 510(k) Number	yetive, Abdomi	Device Evaluation (ODE)  Mail and  3637